Gastroenterologia: impacto das terapias biológicas no controle da doença de Crohn em adolescentes

Abstract

This article reviewed the use of biological therapies in the management of Crohn's Disease in adolescents, a chronic inflammatory condition of the gastrointestinal tract that requires interventions to prevent long-term complications. The problem addressed was the evaluation of the efficacy and safety of biological therapies, considering the need for treatments that can induce and maintain disease remission, improve quality of life, and reduce associated complications. Therefore, the objectives of this study included the analysis of the different available biological therapies, the comparison of their efficacies and safety profiles, and the evaluation of the impact of these therapies on the quality of life of adolescents. To achieve this, the adopted methodology was a literature review, involving clinical studies and systematic reviews published in major scientific databases. The results obtained indicated that biological therapies, such as tumor necrosis factor inhibitors, integrin antagonists, and interleukin inhibitors, demonstrated efficacy in inducing and maintaining remission, in addition to improving the quality of life of adolescent patients. Infliximab, adalimumab, and certolizumab pegol were effective in reducing inflammatory activity, with infliximab being the first to mark a new era in the treatment of Crohn's Disease. Vedolizumab and ustekinumab provided additional options with favorable safety profiles, especially important for adolescents undergoing prolonged treatment.